Digitoxin medication and cancer; case control and internal dose-response studies

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Digitoxin is known to induce apoptosis in cancer cell lines in vitro.
• This study investigates the cancer incidence in cardiac patients using digitoxin compared to the general population.

Purpose of the Study:

• To determine if digitoxin use in cardiac patients is associated with altered cancer incidence.
• To explore potential anticancer effects of digitoxin in a clinical setting.

Main Methods:

• Utilized plasma digitoxin concentration data from 9271 cardiac patients.
• Employed age and sex-matched controls from the Norwegian Cancer Registry to calculate expected cancer cases.

Main Results:

• The digitoxin-treated population exhibited a higher overall cancer incidence than controls.
• Pre-existing increased cancer risk was noted in the digitoxin group, particularly for leukemia/lymphoma.
• Higher plasma digitoxin concentrations correlated with a reduced risk for leukemia/lymphoma and kidney/urinary tract cancers.

Conclusions:

• Confounding factors like high age and cardiac disease complicate the assessment of digitoxin's anticancer effect.
• Results suggest a potential anticancer role for digitoxin in leukemia/lymphoma and kidney/urinary tract cancers.
• Further prospective clinical trials are necessary to validate digitoxin and related cardiac glycosides as anticancer agents.